IONS - Ionis Pharmaceuticals Inc
IEX Last Trade
47.67
-2.230 -4.678%
Share volume: 2,110,439
Last Updated: Fri 30 Aug 2024 09:59:58 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$49.90
-2.23
-4.47%
View ratios
| Fiscal Date | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | |
| Report Date | 2022-11-09 | 2023-02-22 | 2023-05-03 | 2023-08-09 | 2023-11-02 | 2024-02-21 | 2024-05-07 | 2024-08-01 | |
| Assets | |||||||||
| Total Assets | 2.422 B | 2.534 B | 2.885 B | 2.971 B | 2.934 B | 2.990 B | 2.764 B | 2.691 B | |
| Current Assets | 2.152 B | 2.203 B | 2.543 B | 2.617 B | 2.585 B | 2.642 B | 2.416 B | 2.329 B | |
| Inventories | 20.645 M | 22.033 M | 22.200 M | 25.538 M | 25.634 M | 28.425 M | 30.259 M | 28.723 M | |
| Other Current Assets | 143.173 M | 168.254 M | 159.724 M | 177.872 M | 181.075 M | 184.449 M | 174.060 M | 194.715 M | |
| Short Term Investments | 143.173 M | 168.254 M | 159.724 M | 177.872 M | 181.075 M | 184.449 M | 174.060 M | 194.715 M | |
| Total Receivables | 6.645 M | 25.538 M | 13.914 M | 27.956 M | 142.359 M | 97.778 M | 5.140 M | 27.259 M | |
| Current Cash | 1.982 B | 1.987 B | 2.347 B | 2.385 B | 2.236 B | 2.331 B | 2.206 B | 2.079 B | |
| Total Non-current Assets | 269.845 M | 331.182 M | 342.602 M | 354.377 M | 349.321 M | 348.219 M | 348.253 M | 361.745 M | |
| Property Plant Equipment | 180.806 M | 74.294 M | 85.158 M | 91.634 M | 70.928 M | 71.043 M | 72.795 M | 75.902 M | |
| Other Assets | 59.434 M | 256.888 M | 78.296 M | 86.025 M | 104.083 M | 105.280 M | 106.027 M | 118.904 M | |
| Intangible Assets | 29.605 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 2.422 B | 2.534 B | 2.885 B | 2.971 B | 2.934 B | 2.990 B | 2.764 B | 2.691 B | |
| Total liabilities | 1.828 B | 1.961 B | 2.399 B | 2.543 B | 2.619 B | 2.603 B | 2.467 B | 2.427 B | |
| Total current liabilities | 283.454 M | 311.561 M | 259.221 M | 287.975 M | 404.210 M | 448.090 M | 327.648 M | 306.162 M | |
| Accounts Payable | 20.545 M | 17.921 M | 10.499 M | 24.021 M | 5.615 M | 26.027 M | 13.082 M | 9.243 M | |
| Other liabilities | 294.656 M | 287.768 M | 778.054 M | 764.572 M | 761.972 M | 754.920 M | 740.160 M | 722.455 M | |
| Current long term debt | 4.970 M | 7.535 M | 0.000 | 0.000 | 0.000 | 44.332 M | 44.377 M | 44.422 M | |
| Long term debt | 1.250 B | 1.183 B | 1.184 B | 1.315 B | 1.279 B | 1.230 B | 1.231 B | 1.232 B | |
| Other liabilities | 294.656 M | 287.768 M | 778.054 M | 764.572 M | 761.972 M | 754.920 M | 740.160 M | 722.455 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 594.361 M | 572.887 M | 486.570 M | 428.301 M | 315.460 M | 386.686 M | 296.515 M | 263.698 M | |
| Common stock | 141.950 M | 142.049 M | 142.735 M | 143.098 M | 143.317 M | 143.610 M | 145.538 M | 145.958 M | |
| Retained earnings | -1.377 B | -1.430 B | -1.554 B | -1.639 B | -1.787 B | -1.796 B | -1.939 B | -2.005 B |